Thr72
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.0.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr72  -  RAB8A (human)

Site Information
AGQERFRtITTAyyR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4709152

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 8 ) , immunoprecipitation ( 3 , 4 ) , mass spectrometry ( 4 , 9 , 11 , 12 , 13 , 14 , 15 , 16 ) , mutation of modification site ( 3 , 5 , 8 ) , phospho-antibody ( 1 , 3 , 5 , 6 ) , western blotting ( 1 , 3 , 6 , 8 )
Disease tissue studied:
HER2 positive breast cancer ( 9 ) , luminal A breast cancer ( 9 ) , luminal B breast cancer ( 9 ) , breast cancer, triple negative ( 9 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 3 , 6 ) , breast ( 9 ) , E.coli (bacterial) ( 3 ) , Flp-In T-Rex-293 (epithelial) ( 5 ) , HEK293T (epithelial) ( 1 , 8 ) , HeLa (cervical) ( 8 ) , Jurkat (T lymphocyte) ( 11 , 12 , 13 , 14 , 15 , 16 ) , neutrophil-blood ( 4 )

Upstream Regulation
Putative in vivo kinases:
LRRK2 (human) ( 1 , 3 , 5 , 6 , 8 )
Kinases, in vitro:
LRRK2 (human) ( 2 , 5 , 6 , 7 , 8 ) , MST3 (human) ( 5 , 6 ) , TAK1 (human) ( 5 )
Treatments:
MLI-2 ( 1 , 3 , 5 , 6 ) , PF06447475 ( 8 )

Downstream Regulation
Effects of modification on RAB8A:
activity, inhibited ( 8 ) , intracellular localization ( 1 , 8 ) , molecular association, regulation ( 1 , 3 , 6 ) , receptor recycling, inhibited ( 1 )
Effects of modification on biological processes:
endocytosis, inhibited ( 1 , 8 )
Induce interaction with:
RILPL2 (human) ( 3 , 6 )
Inhibit interaction with:
RAB3IP (human) ( 1 )

References 

1

Mamais A, et al. (2021) Mutations in LRRK2 linked to Parkinson disease sequester Rab8a to damaged lysosomes and regulate transferrin-mediated iron uptake in microglia. PLoS Biol 19, e3001480
34914695   Curated Info

2

Schmidt SH, et al. (2021) Conformation and dynamics of the kinase domain drive subcellular location and activation of LRRK2. Proc Natl Acad Sci U S A 118
34088839   Curated Info

3

Waschbüsch D, Purlyte E, Khan AR (2021) Dual arginine recognition of LRRK2 phosphorylated Rab GTPases. Biophys J
33887226   Curated Info

4

Karayel O, et al. (2020) Accurate MS-based Rab10 phosphorylation stoichiometry determination as readout for LRRK2 activity in Parkinson's disease. Mol Cell Proteomics
32601174   Curated Info

5

Vieweg S, et al. (2020) PINK1-dependent phosphorylation of Serine111 within the SF3 motif of Rab GTPases impairs effector interactions and LRRK2-mediated phosphorylation at Threonine72. Biochem J 477, 1651-1668
32227113   Curated Info

6

Waschbüsch D, et al. (2020) Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2. Structure
32017888   Curated Info

7

Schmidt SH, et al. (2019) The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain. Proc Natl Acad Sci U S A 116, 14979-14988
31292254   Curated Info

8

Rivero-Ríos P, et al. (2019) The G2019S variant of leucine-rich repeat kinase 2 (LRRK2) alters endolysosomal trafficking by impairing the function of the GTPase RAB8A. J Biol Chem 294, 4738-4758
30709905   Curated Info

9

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

10

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

11

Mulhern D (2012) CST Curation Set: 13829; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XpSX(K/R)
Curated Info

12

Mulhern D (2011) CST Curation Set: 12684; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

13

Mulhern D (2011) CST Curation Set: 12686; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

14

Mulhern D (2011) CST Curation Set: 12680; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

15

Mulhern D (2011) CST Curation Set: 12682; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

16

Zhou J (2009) CST Curation Set: 6054; Year: 2009; Biosample/Treatment: cell line, Jurkat/TPA; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (F/Y/M)Xp[ST](L/I/M)
Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.